Skip to main content
Molecules to Medicine

Molecules to Medicine

Demystifying drug development, clinical research, medicine, and the role ethics plays


From the Holocaust to Thalidomide: A Nazi Legacy

I was attending World Federation of Jewish Child Survivors of the Holocaust and Descendants 24th Annual International Conference in Cleveland last week, when my aunt, herself a survivor, handed me a copy of Newsweek with a cover article, “The Nazis and Thalidomide: The Worst Drug Scandal of All Time." The story was prompted by the drug developer, Germany’s Grünenthal, unexpectedly issuing an apology to the victims of its teratogenic drug—babies who sustained life-long wounds inflicted by their drug more than 50 years earlier.I’ve written some about thalidomide previously, in my initial Clinical Trials for Beginners posts, (here and here)...

November 8, 2012 — Judy Stone

An Emergency Room's Closure: A Community's Betrayal

Although I've been busy traveling again, the struggle of the Boothbay peninsula communities to keep their hospital remains constantly on my mind. I've written two letters to the editor of the Boothbay Register*, which I am reproducing here to update my readers, as this is an example of broader David and Goliath healthcare struggles and a case study of a crisis in rural healthcare.The proposed closure of the ER is scheduled for April, 2013...

October 26, 2012 — Judy Stone

Drugs in Search of a Disease Pharma Targets Women

Last week I focused on drug advertisement for “Low T” catching up with all the attention given to menopausal women with declining hormones. But women still are the primary targets for pharmaceutical advertising, in part because they can be captured for multiple products—if not quite from the cradle, at least from puberty, through pregnancy, to menopause and to grave.What are some of the consequences of this relentless focus on women’s hormones and common symptoms?...

October 2, 2012 — Judy Stone

Blog Index

Scroll To Top